As nothing is known about Gpr125 in mammary tissue we began by analyzing mRNA levels over the course of mammary development by qRT-PCR (Supplementary Fig. 1a). Gpr125 mRNA was raised during puberty, decreased as mice reached maturity (12 weeks), was higher in earlier compared to later stages of pregnancy and peaked as the gland involuted. This temporal pattern indicates that Gpr125 mRNA is elevated when the gland is actively remodeling during ductal elongation, side-branching, and involution, and decreases as the gland differentiates.

To locate Gpr125 protein expression, we X-gal stained tissue from Adgra3^lz/+ mice in which β-galactosidase (β-gal) is fused to the first transmembrane region of Gpr125 (Fig. 1a, Supplementary Fig. 1b, d). Adgra3^lz/+ mice are viable, fertile, and indistinguishable from wildtypes (Supplementary Fig. 1e). Adgra3^lz/lz mice display mild impairment in ductal elongation during early puberty (Supplementary Fig. 1f, g) but later stages of mammary development are unaffected (Supplementary Figs. 1e, h–l and 2) and dams can lactate. Both genotypes show identical patterns of reporter expression. Gpr125-β-gal was expressed throughout the dormant pre-pubescent mammary tree (Fig. 1b, c). As pubertal ductal elongation began, the X-gal staining pattern partitioned. Weak staining was retained in nipple-proximal ducts (Fig. 1d–f) and persisted there throughout postnatal development. In contrast, robust Gpr125-β-gal expression appeared in proliferative TEBs (Fig. 1d–f). This became reduced to an intense dot at ductal tips when the TEB reached the edge of the fat pad and regressed (arrows Fig. 1e). In histological sections, Gpr125-β-gal was found in cap cells (Fig. 1g) and also in single cells dispersed among the basal layer of mature ducts (Fig. 1g, inset). Gpr125-β-gal localized in cells expressing SMA, p63, and low K14 (Fig. 1h–j) and was absent from cells expressing E-cadherin (Ecad), estrogen receptor (ER), and progesterone receptor (PR) (Fig. 1k–m). Co-expression of Gpr125-β-gal with proliferating cell nuclear antigen (PCNA) and exclusion of p27 indicated their proliferative potential (Fig. 1n, o).Fig. 1

a Left: Schematic of Gpr125 protein, Right: Gpr125-β-gal fusion protein. N-terminus (N), leucine-rich repeats (LRR), immunoglobulin-like domain (Ig), hormone-binding domain (HBD), GPCR autoproteolytic-inducing (GAIN) domain, transmembrane region (TM), and cytoplasmic region (C). b–f Gpr125-β-gal expression in mammary whole mounts from pre-pubertal (3w n = 5) and pubertal (4w n = 4) (5w n = 2) and (6w n = 11) nulliparous mice. Scale bar = 2 mm. g Section of X-gal (blue) stained mammary whole-mount counterstained with nuclear fast red (NFR), shows Gpr125 expression in the cap cell layer of terminal end buds (TEB) and in cells dispersed along the basal layer of subtending ducts (arrows) n = 4. The inset box is a higher magnification of the area indicated by arrows. h–m X-gal (blue) stained sections of TEB with immunolocalization (brown stain) of (h–j) basal markers: smooth muscle actin (SMA), p63, Keratin (K14); Note the occasional cells expressing Gpr125 within the body layer all express basal cap cell markers; k–m luminal markers: E-cadherin (Ecad), estrogen receptor (ER), progesterone receptor (PR); n, o markers of proliferative status: (n) proliferating nuclear cell antigen (PCNA) and (o) p27. Scale bar = 50 µm. n = 3 mice (h–k, n = 3, l, m, o, n = 2 mice/antigen).

We interrogated the effect of hormonal deficiency and supplementation on the proliferation of Gpr125+ cells (Supplementary Fig. 3). Ovariectomized mice impaired in TEB formation, failed to upregulate expression of Gpr125 at ductal tips or to elongate the ductal system (Supplementary Fig. 3a), and showed very low levels of proliferation as detected by 5-ethynyl-2′-deoxyuridine (EdU) incorporation (Supplementary Fig. 3e). Delivery of estradiol to young ovariectomized mice restored TEB formation, ductal outgrowth, and Gpr125 expression (Supplementary Fig. 3b). EdU incorporation (Supplementary Fig. 3f–h) indicated proliferation in both Gpr125+ cap cells (gray stain arrowheads) as well as Gpr125- body cells (asterisks). Mammary glands from adult ovariectomized mice were quiescent (Supplementary Fig. 3c) but administration of estradiol and progesterone-induced pregnancy-like arborization with Gpr125 expression at branch tips (Supplementary Fig. 3d). As Gpr125+ cells do not express hormone receptors (Fig. 1k–m) we conclude that their proliferation is stimulated indirectly by hormonal action on neighboring luminal cells.

To identify the subset of basal cells expressing Gpr125-β-gal we performed flow cytometry on suspensions of total mammary epithelial cells (MECs) from 6-week-old pubertal Adgra3^lz/+ mice using a fluorogenic β-gal substrate: Fluorescein di-β-D-galactopyranoside (FDG) (Fig. 2a). Gating for Gpr125+/FDG+ cells enriched for cells within the basal (CD24^med/lowCD49f^+/Hi) population (right panel); FDG^_ cells were concomitantly depleted within this gate (center panel). Of note, within the basal population, Gpr125+/FDG+ cells displayed the highest level of integrins α6 and β1 (CD49f and CD29) (Fig. 2b), which are defining hallmarks of regenerative MRU/MaSCs^19,20. Conversely, Gpr125+/FDG+ cells were low for the luminal progenitor marker CD61 (integrin β3) and negative for Sca-1, which is expressed on more committed cell types¹⁹. These data show that Gpr125 is expressed in cells towards the apex of the mammary hierarchy.Fig. 2

a Representative FACS dot plots of total MECs (left) isolated from 6-week Adgra3^lz/+ pubertal mice stained with antibodies against CD24 and CD49f. n = 4 mice/ experiment and repeated five times. The basal population is depleted in FDG‒ populations (center). Gpr125+/FDG+ cells gated within the CD24^med/low/CD49f^+/hi basal population (right). b Histograms showing expression of CD49f, CD29, Sca1 and CD61 in Gpr125+/FDG+ (red line), Gpr125^‒/FDG^‒(black line) and total MECs (gray line) n = 4 mice/experiment repeated three times. c Detection of reporters in the cap cell layer of TEBs: left panel: co-expression of s-SHIP-EGFP detected by immunohistochemistry (brown), on top of Gpr125-β-gal detected by X-gal (dark blue) counterstained with hematoxylin (purple); and individual expression in center panel: Gpr125-β-gal detected by X-gal (blue); right panel: s-SHIP-EGFP fluorescence (green). Scale bar = 50 µm (n = 2 mice/panel). dAdgra3 and Lgr5 mRNA expression in the basal cell cluster, visualized by t-SNE plots extracted from the Tabula Muris dataset⁴². e–g RNA-seq based transcriptomic comparison of FACS-sorted Gpr125+ with Gpr125‒ cells isolated from TEB-distal (purple) and nipple-proximal regions (yellow) of pubertal Adgra3^lz/+ mammary glands. e Venn diagram shows 140 differentially expressed genes (gray) are shared by TEB-distal and nipple-proximal Gpr125+ cells (twofold change, FDR = < 0.1). Biological significance was evaluated by (f) gene ontology (GO) and (g) gene set enrichment analysis (GSEA) analysis of TEB-distal and nipple-proximal Gpr125+ cells compared to their Gpr-negative basal cell counterparts. GSEA shows a correlation between genes highly expressed in TEB-distal (blue) or nipple-proximal (yellow) Gpr125+ cells compared to the ‘Lim_mammary_stem_cell_UP’ gene signature. h Volcano plot comparing gene expression of nipple-proximal Gpr125+ cells and TEB-distal Gpr125+ including highlighted candidates in nipple Gpr125+(blue dots) and TEB cells (red dots) (FDR = 0.1). i GO analysis yielded gene enrichment in biological processes (red bars) and molecular function (green bars) that characterize Gpr125+ cells (FDR B&H). j Differently expressed genes between TEB-distal Gpr125+ and nipple-proximal Gpr125+ cells were confirmed and mapped to distinct basal cell clusters by scRNAseq analysis of the pubertal dataset of Pal et al.²⁸. KNetL plots are shown for cell populations expressing Adgra3, Krt14, Tcf7, Sox11, Fbln1, Lrfn5, Lgr5, Slpi Wnt10a, Wnt5a, Wnt6. k Distal Sox11 expression in TEBs is detected in Tcf1⁺ cap and Tcf1^‒ body cells and some adjacent mesenchymal cells. (n = 4 mice). Scale bar = 50 µm. Source data are provided as a Source Data file.

Next, we generated Adgra3^lz/+;s-SHIP-EGFP double mutants and detected co-expression of their respective reporters by immunofluorescence in all TEB cap cells (Fig. 2c). To examine Gpr125 co-expression with Lgr5, we mined scRNAseq datasets of embryonic, pubertal, and adult MECs (Fig. 2d, Supplementary Fig. 4)^27,28,30,42 and found a subset of cells expressing Gpr125 mRNA co-clustered with Lgr5 populations. Collectively, these results indicate that Gpr125 is expressed in disparate progenitor populations with documented regenerative capacity.

To gain further insight into the transcriptional profile of Gpr125+ cell populations, we performed whole-genome RNAseq on Gpr125+ (FDG+/CD49^hi) and Gpr125- (FDG-/CD49^hi) cells isolated from TEB-distal and nipple-proximal mammary regions of pubertal mice expressing the Gpr125-β-Gal. When compared to their Gpr125-negative counterparts, TEB-distal and nipple-proximal populations shared a core of 140 differentially expressed genes (Fig. 2e, Venn Diagram). Gene Ontology (GO) analysis revealed enrichment within this common core of genes encoding proteins involved in cell adhesion and regulation of cell-matrix adhesion (Fig. 2f histogram gray). The TEB-distal Gpr125+ population was enriched in the expression of genes encoding proteins involved in growth factor, calcium, and cytokine binding and ECM (Fig. 2f histogram purple), whereas the nipple-proximal Gpr125+ cells were enriched in the expression of cell-cell signaling, cell migration and guidance and chemo-repulsion factors (Fig. 2f histogram yellow). Gene set enrichment analysis (GSEA) confirmed that both TEB-distal and nipple-proximal Gpr125+ populations are significantly enriched in the Mammary Stem Cell-UP gene signature derived from MRU/MaSC cells (Fig. 2g). When we compared TEB-distal and nipple-proximal Gpr125+ cells to each other (Fig. 2h, volcano plot and 2i) TEB-distal Gpr125+ cells showed significantly increased expression of mRNA encoding stem cell markers such as Aldh1a3, promigratory cell-cell and cell-matrix factors such as fibronectin, fibulin1, as well as the homophilic cell adhesion molecule, Lrfn5 that promotes neurite outgrowth. Of note, the highest expressed gene in this population was Sox11 (SRY-related high-mobility-group (HMG) box 11), which encodes a transcription factor implicated in breast cancer invasion, that is responsible for keeping cells in a hybrid epithelial-mesenchymal state and is a key regulator of stem and progenitor cells^38–41. In contrast, nipple-proximal Gpr125+ cells showed high expression of genes encoding protease inhibitors Serpin and Slpi that maintain elastin integrity as well as chemotactic guidance factors, such as Robo4, and Cxcl9 and the Wnt pathway agonist, Rspo1.

To confirm specific differences in gene expression between the two pubertal Gpr125 subpopulations, we analyzed the pubertal scRNAseq dataset of Pal et al²⁸. While t-SNE plots partitioned the basal population into two groups (Supplementary Fig. 4b), KNetL dimensionality reduction⁴³ was able to resolve eight clusters permitting more detailed observation (Fig. 2j and Supplementary Fig. 4c). Acta2 encoding the basal marker SMA, was expressed in all 8 clusters (Supplementary Fig. 4c). Adgra3 was induced in clusters 4–7 (Fig. 2j). Lgr5 expression, which is restricted to nipple-proximal cells, was found in cluster 4 whereas Sox11 and Tcf7 were expressed in clusters 5–8 (Fig. 2j). To confirm distal expression Sox11 and Tcf1 (encoded by Tcf7) at the protein level we performed immunofluorescence microscopy. Tcf1 was found exclusively within the nuclei of cap cells. Sox11 showed prominent nuclear localization in both cap and body cells of the TEB as well as in some neighboring stromal cells (Fig. 2k). In keeping with the role of Sox11 in maintaining a hybrid epithelial-mesenchymal cell state, we noted that clusters 5–8 showed significantly lower levels of Krt14 and Krt5 expression than clusters 1–4 (Fig. 2j, Supplementary Fig. 4c). The KNetL plots confirmed Slpi expression specifically in nipple-proximal cluster 4, expression of Lrfn5 and Fbln1 specifically within TEB-distal clusters and also found distinct expression patterns of genes encoding Wnt ligands: Wnt10a was expressed in nipple-proximal cluster 4 and Wnt5a and Wnt6 in the TEB-distal clusters 5–8 (Fig. 2j). Collectively, our analyses show that Gpr125 encompasses distinct progenitor populations in the mammary gland that share a common gene expression core as well as site-specific transcriptional profiles.

To position pubertal Gpr125+ cells within the mammary hierarchy, we carried out lineage tracing to determine their physiological potency. We generated a mouse strain harboring a CreER^T2 module inserted after the endogenous Adgra3 promoter (Fig. 3a and Supplementary Fig. 1b, c), crossed them to the Tomato (tdT) lineage reporter strain (B6.Cg-Gt(ROSA)26Sor^{tm14(CAG-tdTomato)Hze/J}) and initiated tracing in 5-week-old female progeny by delivering Tamoxifen (Tam) via intraperitoneal (IP) injection (Fig. 3b). After two weeks we observed clusters of tdT+ cells within the basal layer of ducts (Fig. 3) that were most abundant in the nipple-proximal region (Fig. 3c). tdT+ cells displayed the characteristic bipolar shape of myoepithelial cells and by immunofluorescence, co-localized with the basal markers K5, K14, SMA, and p63 (Fig. 3d–g) and were devoid of the luminal markers Ecad and K8 (Fig. 3h, i). tdT was also found in cap cells of TEB (Fig. 3j–l) and in strips of cells extending down the basal surface of subtending ducts.Fig. 3

a Genetic strategy used to target tdTomato expression to Gpr125/Adgra3-expressing cells and their progeny. b Schematic illustrating strategy to trace the lineage of cells that express Gpr125 during early puberty by delivering Tamoxifen (Tam) to (5w) nulliparous mice and harvesting glands during late puberty (7w), pregnancy (P15); lactation (L6), and in aged and multiparous mice. c Representative 3D-imaging of mammary gland nipple-proximal region of Adgra3-CreER^T2;tdT mice analyzed 2 weeks after labeling. d–g tdT+ cells with immunolocalization (green) of basal markers K5, K14, SMA, and p63, and exclusion of luminal markers Ecad, K8 (h, i). j tdT+ cells in the cap cell layer of TEB and subtending duct with immunolocalization of basal K5 (k) and exclusion of luminal Ecad (l). m p15 Immature alveoli show basally located tdT+ cells that express K5, but lack K8 expression (n). o tdT+ cells form characteristic basket-like morphology of mature myoepithelial cells enmeshing an Ecad+ alveolus in the lactating mammary gland. p–r Extensive strips of tdT+ cells remain along the outer basal layer of ducts in aged mice (p, q) and after multiple pregnancies (r). Scale bar = 50 µm. tdT = red, tdT+ cells; DAPI = blue nuclear staining. Two glands from each of the five mice were analyzed/stage.

Next, we mated mice in which tracing had been initiated during puberty and analyzed their glands during pregnancy. Again, tdT+ cells were basally restricted. At p15.5 clusters of tdT+ cells colocalized with K5-expressing cells (Fig. 3m) surrounding immature Ecad+ alveoli (Fig. 3n). At lactation day 6 (L6), tdT+ cells displayed the typical basket-like features of contractile myoepithelial cells, enmeshing fully differentiated Ecad+ alveoli (Fig. 3o, Supplementary movie 1).

We addressed the longevity of the Gpr125+ progenitors labeled during puberty by tracing their tdT+ progeny in both aged nulliparous mice (Fig. 3p, q) and multiparous mice (Fig. 3r). In both, clusters and extensive strips of elongated tdT+ cells were found along basal ductal borders. Collectively, our lineage tracing results reveal that Gpr125 identifies unipotent basal progenitors present in the permanent ductal system during puberty that are long-lived and retain progenitor activity after multiple pregnancies and throughout the average lifespan of the mouse.

To assess Adgra3 mRNA during pregnancy we examined the scRNAseq data of Bach et al. focused on gestational changes in wildtype cells and found Adgra3 mRNA is highly upregulated in Bsl2 and BslG populations beginning ~p4.5 and peaking ~p14 (Fig. 4a–c)⁴⁴. Adgra3 appears at #23 in the list of differentially expressed marker genes for Bsl2 and #63 for BslG population (https://crukci.shinyapps.io/brca1tumourigenesis/)⁴⁴.Fig. 4

a UMAP plot and violin plot (b) showing Adgra3 expression restricted to the mammary basal populations. c Violin plot showing expression levels at days of gestation (dG) as indicated in Basal 2 and Basal G cell types⁴⁴. d–f X-gal (blue) stained mammary whole mounts from pregnant mice Scale bar = 500 µm (n = 4 mice/stage) showing Gpr125-β-gal expression at d sites of emerging side-branches at 12.5 days of pregnancy (p12.5), e tips of elongating side-branches at p13.5, and f in ducts but not alveoli at p15.5. g, h X-gal (blue) stained sections of a permanent duct and side branch with immunolocalization (brown) of basal marker p63 and K14. Scale bar = 20 µm (n = 2 mice). i–l X-gal (blue) stained sections counterstained with NFR. Boxed insets are higher magnification of regions indicated by arrows (n = 2 mice/stage). m Schematic illustrating strategy to trace the lineage of cells that express Gpr125 during early pregnancy by delivering Tam at p14.5 and harvesting glands at p20.5 and L6 mice. n tdT+ SMA+(red/green) cells were found in ducts and alveoli at p20.5 and at birth (o). p Fully differentiated tdT+ cells were devoid of luminal Ecad marker (green) at L6. Scale bar = 50 µm. tdT = red, tdT+ cells; DAPI = blue, nuclear staining. One gland from each of the five mice was analyzed.

To investigate Gpr125 protein expression during early pregnancy (p12-13.5) we again detected Gpr125-β-gal expression by X-gal staining. Gpr125-β-gal appeared focally where side-branches emerge from ducts and concentrated at branch tips (Fig. 4d–e, g–j). X-gal staining was prominent along the basal layer of permanent ducts during late pregnancy but was absent from differentiating alveoli (Fig. 4f, k, l) with the exception of rare Gpr125-β-gal+ cells that likely represent the branch tip of each alveolar cluster (Fig. 4k arrowheads).

To interrogate the potency of Gpr125+ cells present during pregnancy we initiated lineage tracing in mid-pregnant mice at p13.5 and analyzed their glands just prior to birth and during lactation (Fig. 4m). Again, tdT+ cells exclusively displayed myoepithelial characteristics (Fig. 4n–p).

Having established that Gpr125 cells are unipotent during postnatal mammary development, we next assessed their plasticity in a regenerative setting by using a lineage tracing approach combined with a transplantation assay. We induced lineage tracing by delivering Tam to 5-week-old mice then two weeks later harvested and prepared MECs from one of their #4 inguinal glands and transplanted them into FoxN1^nu recipients (Supplementary Fig. 5a). Glands were harvested from both the donor and host after two and three weeks and their labeled cell progeny were compared. As expected the Gpr125 lineage in glands remaining in the donor was exclusively basal (Supplementary Fig. 5b–d). In contrast, a mixed basal and luminal lineage was generated within the reconstituted trees of transplant recipients (Supplementary Fig. 5e) indicating that in the context of experimentally induced regeneration Gpr125+ cells regain bipotency.

Extending our studies to embryonic mammary development, we found that early Adgra3^lz/+ embryos showed diffuse ectodermal Gpr125-β-gal expression that by E14.5 concentrated into ectodermal appendages, such as whisker follicles but was absent from the mammary line, placodes and buds (arrows Fig. 5a, a’). However, at E15 Gpr125-β-gal appeared in the mammary sprout (arrows Fig. 5b, b’), coincident with the onset of proliferation, indicated by nuclear PCNA and bromodeoxyuridine (BrdU) (Fig. 5c, d), and was concentrated towards the leading tip together with K14 and p63 (Fig. 5e, f). At this stage Gpr125-β-gal also became concentrated in the “bulge” stem cell compartment of hair follicles and whiskers (Supplementary Fig. 6). At E18.5 Gpr125-β-gal was strongly expressed in the rudimentary tree (Fig. 5g) and concentrated in the lactiferous duct and the multilayered branch tips (Fig. 5h). Although K14 expression was present in most cells (Fig. 5i) and K18 was increased in central cells (Fig. 5j), Gpr125+ branch tips lacked both keratins (Fig. 5i, j arrow and insets) but expressed p63 (Fig. 5k arrow and insets).Fig. 5

a, b X-gal (blue) stained Adgra3^lz/+ embryos at embryonic day (E)14 (a) and E15 (b). Arrows indicate mammary buds and sprout respectively magnified in boxes below. Scale bar = 200 µm (n = 2 litters/stage). a’–f Gpr125-β-gal expression in sections of E14 buds (a’) and E15 sprouts (b’–f), with immunolocalization (brown) for proliferative markers PCNA and BrdU (c, d), and for K14 and p63 (e, f). Scale bar = 50 µm (n = 2 embryos/stage). g X-gal (blue) stained skin whole mount showing Gpr125-β-gal expression in the E18.5 tree and hair follicles encircling the developing nipple zone. Scale bar = 1 mm. (n = 2 litters of embryos). h–k Sections of the E18.5 rudiment tree stained with X-gal (blue) followed by NFR counterstain (h) or immunochemical detection (brown) of K14, K18, and p63 (i–k). Boxed insets are higher magnification of branch tips regions indicated by arrows. Scale bar = 50 µm (n = 2 embryos/stage). l Tracing of Gpr125+ cells in E14.5 or E19.5 embryos were initiated by delivering Tam to pregnant Adgra3^cre/cre dams mated to Rosa26^tdT mice. Mammary tissue from the progeny was analyzed at 8 weeks of age. m–o 3-D images showing representative regions of pubertal ducts from E14.5 labeled embryo containing clusters of basally located tdT+ cells that co-express the basal marker SMA (green) (m) as well as tdT+ columnar luminal cells lacking SMA (n) and expressing luminal marker Ecad (green) (o). p Glands from progeny labeled at E19.5 show basally restricted tdT+ cells devoid of Ecad. tdT = red, tdT+ cells; DAPI (blue) nuclear staining. Scale bar = 50 µm. Two glands from each of the three mice were analyzed/stage.

To test the potency of embryonic Gpr125+ cells we crossed Adgra3^cre/cre to Rosa26^tdT mice and administered Tam to the pregnant dams to label embryos (Fig. 5l) then analyzed these pups at 8 weeks of age. Glands from mice labeled at E14.5 revealed tdT not only in basally located bipolar cells co-expressing SMA (Fig. 5m), but also in columnar cells situated above the SMA + basal layer (Fig. 5n) that expressed the luminal marker Ecad (Fig. 5o). By contrast, when tracing was initiated at E19, tdT+ cells were exclusively basal, bipolar, and SMA+ (Fig. 5p).

These data show that Gpr125 appears at the onset of directed growth in a bipotent progenitor population expressing markers of both lineages (K14/K18). However, before birth Gpr125 cells become lineage-restricted and from thereon function as unipotent basal progenitors. Of note, Gpr125 expression concentrates at this stage in undifferentiated p63⁺K14-/K18⁻ cells at branch tips poised for a ductal extension.

Next, we investigated Gpr125 in mouse breast cancer models. Gpr125 showed the highest mRNA expression in MMTV-Wnt1 mice (Supplementary Fig. 7a) which develop mixed-lineage tumors enriched in cells with MaSCs profiles and show transcriptomic resemblance to basal-type breast cancer^45–49. We, therefore, generated MMTV-Wnt1; Adgra3^lz/+ mice and analyzed glands over the course of tumor progression. In 8-week-old mice, Gpr125-β-gal was expressed exclusively in basally located cells within the nipple proximal hyperplasia and on hyperbranched tips (Fig. 6a–d). Robust expression was seen in tumors, where Gpr125+ cells formed large homogenous regions and concentrated at pushing margins (Fig. 6e–h). Although Wnt-1 tumors display regions composed of K14+ and K18+ bilayers these populations rarely overlapped with Gpr125. Gpr125+ cells also lacked both SMA and K8 and although some expressed K14, the majority lacked both keratins (Fig. 6g–i). They did, however, express p63 as well as Tcf1 (Fig. 6j, k). To determine the effect of Wnt expression on the potency of Gpr125 expressing cells, we generated MMTV-Wnt1;Adgra3^cre/+; Rosa26^tdT mice and performed lineage tracing by delivering Tam to 5-week old pubertal mice and harvesting hyperplastic glands from 12-week old mice (Fig. 6m). tdT was found in both SMA+ and Ecad+ cells (Fig. 6n, o). Gpr125 cell progeny were concentrated at tips of invasive branches (Supplementary movie 2). These data indicate that in the context of MMTV-Wnt1 transformation pubertal Gpr125+ cells retain the undifferentiated mesenchymal characteristics of TEB cap cells and the bipotency of embryonic progenitors.Fig. 6

a–c X-gal (blue) stained mammary whole mounts from 8-week-old MMTV-Wnt1;Adgra3^lz/+ mice (n = 23 mice) show robust Gpr125-β-gal expression in hyperbranched ductal tips (c) and nipple-proximal zones compared to (b) control Adgra3^lz/+ littermate. d X-gal (blue) section of hyperbranched ductal tip counterstained with NFR presenting basal restriction of Gpr125-β-gal expression in 12-week-old MMTV-Wnt1;Adgra3^lz/+ mice. e-h X-gal (blue) stained whole mount and sections counterstained with NFR of MMTV-Wnt1;Adgra3^lz/+ tumor (g–k) showing Gpr125 cells devoid of immunolocalization (brown) for SMA, K14 or K8, but expressing p63 and Tcf1 (n = 4 tumors/marker). l Tcf1 expression (red) in the cap cells of normal TEB (n = 3 mice). m–o Lineage tracing strategy in 5-week-old MMTV-Wnt1;Adgra3^lz/+ produced both (n) K5 + (green) and (o) Ecad + ;tdT + (green/red) cells in hyperplastic glands at 12 weeks. DAPI = blue nuclear staining. One gland from each of the five mice were analyzed.

Wnt1 tumors have been divided into two subtypes with distinct gene expression (ex) profiles: Wnt1-early(ex) and Wnt1-late(ex), which correlate with early (average 6.5 weeks) and late (average 22.5 weeks) tumor onset respectively^45,46. We noted that Gpr125-β-gal expression was consistently more extensive in MMTV-Wnt1; Adgra3^lz/+ tumors with shorter latency (Fig. 7a). By qRT-PCR we confirmed 3-fold higher levels of Gpr125 mRNA in MMTV-Wnt1; Adgra3^lz/+ tumors with very short latency compared to those with long latency (p = 0.0052) (Fig. 7b). Prospective analysis of a microarray dataset for murine mammary cancer models showed that Gpr125 was highest in Wnt-Early(ex) tumors (Supplementary Fig. 7a). To investigate the course of Gpr125+ cell expansion we carried out flow cytometry. In hyperplastic glands, the Gpr125+/FDG+ population localized within the traditional basal gate but in tumors, it was expressed in a population with intermediate CD49 levels (Fig. 7c) that was more pronounced in uninvolved glands and tumors that arose early. Collectively, these data show that expansion of the Gpr125 tumor population correlates with early tumor onset in mice. We further investigated GPR125/ADGRA3 expression in human breast cancer patients within the METABRIC and the TCGA datasets downloaded from the cBioPortal platform. ADGRA3 mRNA level was significantly higher (****p < 0.0001, **p = 0.0042) in tumors lacking expression of hormone receptors (Fig. 7d). No correlation was found between ADGRA3 expression and HER2 status (Supplementary Fig. 7c). ADGRA3 expression was significantly higher (*p = 0.0322) with BRCA1 status within the METABRIC but not the TCGA datasets (Supplementary Fig. 7d, e). Elevated ADGRA3 mRNA levels were found in higher grade tumors (Supplementary Fig. 7f). The highest expression of ADGRA3 was found within basal-type breast cancers within in the PAM50 classification of both databases (Fig. 7e, f) and in microarray analyses (Supplementary Fig. 7b). ADGRA3 was significantly higher in the METABRIC integrative cluster 10 (Fig. 7g), defined as a basal-like cancer enriched subgroup with high genomic instability and alteration of key cell-cycle-related genes. Expression of ADGRA3 mRNA was higher in human breast cancer cell lines assigned to Basal A/B categories within the DepMap database (https://depmap.org/portal/) compared to those categorized as luminal or HER2-positive (Fig. 7h and Supplementary Fig. 7h). Interrogating publicly available datasets using the kmplotter algorithm showed that higher GPR125 levels within the basal subtype correlated with worse patient outcome in terms of relapse-free survival (p = 0.0054) and distant metastasis-free survival (p = 0.0043) (Fig. 7i, j red line), and this was confirmed using the BreastMark algorithm for disease-free survival (Supplementary Fig. 7g, blue line). Last we found that particularly high GPR125 expression correlated with poor distant metastasis free survival in the Basal-Like 1 (BL-1) triple-negative breast cancer (TNBC) subgroup (Fig. 7k).Fig. 7

a X-gal/NFR stained sections showing higher Gpr125-β-gal expression in a short (7w) latency MMTV-Wnt1;Adgra3^lz/+ tumor (Wnt1-early) versus a long (36w) latency (Wnt1-late) tumor. Scale bar 100 µm and 50 µm. (n = 5 tumors/subtype). b qRT-PCR analysis of relative Adgra3 mRNA expression in early and long latency tumors MMTV-Wnt1;Adgra3^lz/+ tumors (n = 3 tumors/subtype, **p = 0.0052). c Representative FACS dot plots of total MECs isolated from MMTV-Wnt1;Adgra3^lz/+ hyperplastic uninvolved glands and associated short and long latency tumors stained with CD24 and CD49f. FDG+ cells in: 36w tumor = 13331; 36w hyperplasia = 4048; 7w tumor = 64889; 7w hyperplasia = 13156. Plots are representative of three independent experiments. dADGRA3 expression in (left) ER- (n = 445) and ER+ (n = 1459) and in (right) PR- (n-895) and PR+ (n = 1009) BC patient samples from the METABRIC dataset **p = 0.0042, ****p < 0.0001. e, fADGRA3 expression in BC patient samples from TGCA PanCancer Atlas (n = 1084) (e) and METABRIC (n = 2509) (f) datasets classified using the PAM50 geneset; ****p < 0.0001. g Integrative clusters within the METABRIC dataset showing high ADGRA3 expression levels in cluster 10; ****p < 0.0001, Mann–Whitney test two tailed. hADGRA3 expression in human breast cancer cell line from Depmap database (https://depmap.org/portal/) **p = 0.0068, ***p = 0.0002, Unpaired t test two-tailed. i–k Kaplan–Meyer curves depicting ‘Relapse-free survival’ and ‘Distant Metastasis-Free Survival’ in months for high (red lines) and low (black lines) ADGRA3 mRNA expressing human basal-type (h, i) and basal-like-1 TNBC (j) breast cancer subtypes. Auto best fit cutoff was used to divide patients into high and low expression (indicated in beehive plots) sourced from (https://kmplot.com/analysis/index.php?p=service&cancer=breast) KMplotter⁷⁵. logrank p-value and Hazard Ratio (HR) indicate a significant association between high expression and poor prognosis. Each scatter dot plot represents the mean ± SEM. Source data for this figure are provided as a Source Data file.

All studies involving animals received ethical approval by the Institutional Animal Care and Use Committee (IACUC) at NYU School of Medicine under protocols 202000144 and TR201900137/IA16-00513. All mice were housed in individually ventilated cages under a 12:12 h light–dark cycle with water and food available ad libitum and monitored daily in an ALAC accredited facility, and euthanized by CO₂ anesthesia followed by cervical dislocation. Tumors induced in transgenic breast cancer models were not allowed to exceed 2 cM in diameter or 5% of body weight in accordance with IACUC guidelines.

Males and females of the following strains were maintained as breeding stock. Females only were used in all analyses.

Adgra3^cre mice were constructed by Ingenious Technologies, Ronkonkoma, NY as follows. A cassette containing CreER^T2 followed by a 3’ polyadenylation signal, harboring SV40-driven Neo flanked by FRT sites inserted in a central intron, was recombined into a bacterial artificial chromosome (BAC) to place CreER^T2 under the control of the Adgra3 promoter, excising 502 bp encompassing 221 bp of exon 1 and part of the following intron 1-2 of Adgra3. ES cells were selected for germline transmission by PCR, verified by southern analysis and sequencing then bred to B6.Cg-Tg(ACTFLPe)9205Dym/J (JAX: 005703) strain to remove Neo. These mice were crossed to FVB/N and B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J (JAX: 007914) and maintained thereafter on a mixed strain background. Adgra3^cre/cre mice have been made available through the Mutant Mouse Resource and Research Center (MMRRC) Stock No. 068344 (https://www.mmrrc.org/catalog/sds.php?mmrrc_id=68344). Adgra3cre/+ were crossed to B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J (JAX:007914) reporter strain for lineage tracing experiments. Tracing was activated at 5 weeks as well as during pregnancy P14.5 and P19.5 and tissue were harvested from mice 48 hrs later and at developmental time points 7, 8, 24, and 36 weeks, P15, P20.5, L6. For histological analysis, Adgra3^cre/+ and Adgra3^cre/cre tissue were harvested at 6 weeks, P12.5, and involution days 3, 11, and 21.

Adgra3^lz/+ mice⁴, kindly provided by Regeneron, were rederived and backcrossed onto an FVBN background. This strain was generated using VelociGene methods⁶⁵ to modify a bacterial artificial chromosome (BAC) clone carrying the mouse Adgra3 gene by replacement of sequence encompassing exons 16–19 with lacZ to produce expression of fusion protein comprising the N-terminal extracellular domain, the first transmembrane domain, and part of the first intracellular loop of Gpr125 fused to β-galactosidase (Fig. 1a). Their mammary tissue was harvested during puberty (5–7 weeks of age) for flow cytometry, RNAseq, ductal elongation, and hormonal deprivation/supplementation studies. For X-Gal localization studies, tissue was harvested from nulliparous mice at day 2, day 18, weeks 3, 4, 6, 8, 12, 26, and 36, during early, mid and late pregnancy (P12, P13.5, P16.5, P18.5), lactation, involution days 1, 3, 5,10, 21 and from multiparous mice after 2 cycles of pregnancy and lactation (L6) and involution and from embryos at E14, E15, and E18.5.

MMTV-Wnt1 mice (FVB.Cg-Tg(Wnt1)1Hev/J Jax Strain #002934) were crossed to the above strains. Hyperplasia was analyzed at 7–8 weeks and tumors were collected before exceeding 2 cM in diameter or 5% of body weight in accordance with IACUC guidelines. These tissues were analyzed for Adgra3-β-gal expression, histology, and flow cytometry

Lgr5-EGFP-IRES-CreER (B6.129P2-Lgr5tm1(cre/ERT2)Cle/J Jax Strain #008875) and sSHIP-EGFP (B6.Cg-Tg(Inpp5d-EGFP)DLrr/CprJ Jax Strain #024808) mice were backcrossed onto on an FVBN background then to Adgra3^lz/+ for immunolocalization and FACS experiments. Prepubertal 3-week old homozygous CrTac:NCR-Foxn1^nu(NCRNU) (Taconic) females were used as hosts for mammary cell transplantation assays.

All mice were analyzed using a standard cycle of 1 min each 94 °C, 58 °C, 72 °C for 30 cycles on a Perkin Elmer (Waltham MA) DNA Thermal Cycler Machine and the PCR products were visualized on a 2% agarose gel containing 0.2μ g/mL ethidium bromide (Sigma-Aldrich, St. Louis, MO). Oligonucleotide primers: Adgra3-cre-F 5′-TAA AGA TAT CTC ACG TAC TGA CGG TG-3′ and Adgra3-cre-R 5′-TCT CTG ACC AGA GTC ATC CTT AGC-3′, Adgra3-wt-F 5’-ACG CTG CCC AAC CGC A-3′ and Adgra3-wt-R 5′-AAA GCA GGG ATGGCA TGG GAC G-3′; Adgra3-lacZ-F 5′-ATG TTA GCT TAA ATG GAC TGT C-3′, Adgra3-lacZ-R 5’-GTC TGT CCT AGC TTC CTC ACT G-3′; Adgra3-wt-F 5’-AGA TGC ACC AAG GAA GCC AG-3′, Adgra3-wt-R 5′-ATA AGT AAA TCC CAA AGC TCA C-3′, MMTV-Wnt1-F 5′-GGA CTT GCT TCT CTT CTC ATA GCC-3′, MMTV-Wnt1-R 5’-CCA CAC AGG CAT AGA GTG TCT GC-3′. MMTV-Wnt1, sSHIP-EGFP and Lgr5-EGFP were genotyped according to their respective Jax Lab protocols.

Inguinal mammary glands were harvested, snap-frozen in liquid nitrogen, and homogenized in 1 ml of TRIReagent (Life Technologies) using a hand-held tissue homogenizer (Kinematica, Lucerne, Switzerland), then mixed with 200 μl of chloroform and centrifuged at 14,000 × g for 15 min to eliminate protein debris. The upper aqueous phase was mixed with an equal volume of 70% ethanol and passed through a Qiagen RNeasy mini spin column by 15 s centrifugation at 8000 × g at room temperature (RT). Total RNA bound to the column filters was washed in 350 μl of ethanol-containing buffer (RW1 buffer; Qiagen, Valencia, CA, USA) to remove contaminants and incubated in 10 μl of RNase-free DNase I enzyme (273 Kunitz units; Qiagen) for 15 min at RT to ensure digestion of any residual genomic DNA fragments. The columns were washed according to the manufacturer’s instructions in ethanol-containing buffers (RW1 and RPE buffers; Qiagen). Total RNA was eluted in 50 μl of RNase-free water, and its concentration was determined by Nanodrop measurement. Reverse transcription was performed using 2 μl of RNA (10 ng/μl) from tissue using the QuantiTect Probe RT-PCR Kit (Qiagen; catalog number 204443). Real-time analysis was performed using the ThermoFisher Scientific Taqman Gene Expression Assay ID Mm01211377_m1 for mouse Adgra3 and mouse β2-microglobulin (Mm00437762_m1) as the reference assay. Realtime analysis was performed in the Applied BiosystemsViiA™ 7. Total Adgra3 mRNA levels were normalized to those of mouse β2 microglobulin and plotted as levels relative to tissue from males.

Expression of the lineage reporter harbored by Adgra3-CreER^T2;Rosa26R-lox.STOP.lox-tdTomato (tdT)was initiated by delivering tamoxifen (Tam). For tracing at mid-puberty Tam was delivered IP at low dose: 1.5 mg, and high dose: 5–15 mg (delivered in 2.5 mg aliquots every other day). For tracing during pregnancy and embryogenesis 2 doses of 2.5 mg Tam were given by oral gavage to Adgar3^cre/cre pregnant dams over a 24 h time period. Pups were delivered at E19.5-E20.5 by caesarian section to avoid Tam-induced problems with delivery and fostered by SWR/J mice. No fluorescence was observed in non-induced mice. Specific details of the timing of Tam delivery, age of mice, and intervals for harvesting of tissue are provided in each figure.

Mammary glands were excised and fixed O/N in 4% paraformaldehyde (PFA) (Sigma-Aldrich) then processed using a CUBIC protocol optimized for mammary gland^25,66. Tissue was incubated at 37 °C in CUBIC Reagent 1 A (10 wt% Triton, 5 wt% N,N,N’,N’-tetrakis (2-HP) ethylenediamine, 10 wt% Urea, NaCl 25 mM) clearing solution for 4 days, rinsed 3× in phosphate-buffered saline (PBS), then incubated at 4 °C for 4 days in primary antibodies diluted in PBS with Triton (PBST) containing 10% serum, rinsed again, then incubated at 4 °C in secondary antibody for 2 days, rinsed 3×, then cleared in CUBIC Reagent 2 (50 w/v% Sucrose, 25 w/v% Urea, 10 w/v% Triethanolamine, 0.1 w/v% Triton) at 37 °C for 24 h. Primary rabbit antibodies: anti-K5 (Covance, PRB160P, 1:100); anti-E-cadherin (Cell Signaling, 3195 S, 1:100); anti-p63 (Abcam, ab124762,1:100); anti-K14 (Abcam, Ab181595 1:100); and rat anti-K8 (Developmental Studies Hybridoma Bank, TROMA-I, 1:50); mouse anti-SMA (Dako, M0851, 1:100). Alexa Fluor-conjugated secondary antibodies (Thermo Fisher Scientific 1:500): goat anti-mouse 647 (A21237); goat anti-rat 647 (A21247); goat anti-rabbit 647 (A21245). Cleared mammary tissues were imaged using a Zeiss 880 Laser Scanning inverted confocal microscope with 10X, 20X air Plan-Apochromat N.A. 0.8 M27 objective lenses. Confocal images were displayed with ZEN2 software. This was followed by visualization and analysis in FIJI/Image J v.2.0.0 and Imaris v.9.5.

Embryos and mammary glands were fixed in 4% PFA at RT for 30-60 min, rinsed 3X in X-gal rinse buffer (2 mM MgCl₂, 0.1% Sodium deoxycholate, and 0.2% NP-40 in PBS) at RT, then incubated in X-gal staining solution (50 mg/ml 5-bromo-4-chloro-3-indolyl-β Dgalactopyranoside) in rinse buffer containing 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide) (Applichem, Cheshire, CT) at RT O/N. After staining, glands were rinsed in PBS, post-fixed in 4% PFA O/N then prepared for whole-mount analysis or processed for paraffin embedding, sectioning, and histological analysis.

X-gal stained whole mounts were post-fixed in 4% PFA, washed twice with 1X PBS, dehydrated through an increasing ethanol gradient, cleared of lipids in Carnoy’s Fixative (60% Ethanol, 30% Chloroform, 10% Glacial Acetic Acid) for 2 h, and further cleared in Citrisolv (Fisher Scientific, Suwanne, GA) for 2 h. Glands were pressed flat between the slide and coverslip under a heavy weight for 30 min, and imaged on a Leica dissecting microscope Model WILD M3Z (Leica Microsystems, Bannockburn, IL) with an Optronics digital camera Model 60800 (Goleta, CA). The glands were then re-hydrated through a decreasing ethanol gradient and counterstained with Carmine alum (500 mL distilled water containing 1 g Carmine and 2.5 g aluminum potassium sulfate; Sigma Aldrich, St Louis, MO) diluted 1:4 in distilled water. Glands were once again dehydrated in ethanol, cleared in Carnoy’s Fixative and Citrisolv, and pressed flat before mounting under a coverslip with Cytoseal (VWR, West Chester PA) then re-photographed.

Mammary glands were fixed with either 10% neutral buffered formalin or 4% PFA and embedded in paraffin. Tissue sections on slides were incubated at 60 °C oven for 1 h, rinsed in Citrisolv for 10 min, and rehydrated. Antigen retrieval was performed by microwaving at 900 watts for 30 min in 10 mM Citric Acid buffered to pH 6. From this point forward, the slides were washed thrice with 1× PBS between each step. For immunohistochemistry (IHC), endogenous peroxidase activity was quenched by treating slides with 3% Hydrogen Peroxide (Sigma Aldrich) for 15 min at RT. Slides were blocked with 20% normal goat serum for 30 min to reduce background signal. Primary antibodies were diluted in 2% bovine serum albumin (BSA, Sigma-Aldrich) in 1× PBS, and incubated at 4 °C O/N. Primary rabbit antibodies to: K14 (Covance PRB-155P 1:4000); Tcf1 (Cell Signaling 22035 1:100); Collagen (Rockland1:100), Fibronectin (Sigma F3648 1:100), Sox11 (Millipore ABN105, 1:100), Ki67 (Thermo Scientific 1:100), p63 (Abcam 4262 1:100), progesterone receptor(DAKO A0090 1:500), EGFP (Life Technologies A-11122 1:300) and mouse antibodies to K8 (Progen 65138 undiluted); E-cadherin (BD 610182 1:100); PCNA (Dako M0987 1:500), estrogen receptor (SRA 1010 StressGen 1:100), BrdU (Invitrogen 033900 1:500), p27(Thermo Scientific Ab1 MS-256 1:200) and goat antibodies to P-cadherin (R&D AF761 1:100). For immunofluorescence, Alexa Fluor-conjugated secondary antibodies from (Life technologies diluted 1:500): goat anti-mouse 647 (A21237); goat anti-rat 647 (A21247); goat anti-rabbit 647 (A21245), donkey anti-goat 555, (A21432) were applied for 30 min at RT. For IHC biotinylated secondary antibodies were diluted in 2% BSA/PBS for 1 h at RT, followed by HRP-conjugated Streptavidin (Vector Labs, Burlingame CA) for 30 min at RT. Colorimetric signal was developed using the DAB substrate (Vector Labs).

All reagents were purchased from Stem Cell Technologies (Vancouver, British Columbia) unless otherwise noted. Mice were sacrificed with CO₂ followed by cervical dislocation, and the 3rd, 4th, and 5th mammary glands were harvested and the lymph nodes excised. Glands were minced into a homogeneous slurry added to a 15 mL tube containing 1 mL Collagenase/Hyaluronidase and 9 mL Epicult-B Basal Medium and rotated for 6–8 h at 37 °C. The digests were then vortexed briefly and centrifuged at 450 × g for 10 min. The pelleted epithelial organoids were resuspended in 1 mL of 0.25% Trypsin-EDTA and incubated at 37 °C for 1 min, quenched with HBSS supplemented with 2% FBS (HF), and centrifuged at 450 × g for 6 min. The pellet was resuspended in 1 mL Dispase with 1 mg/mL DNase I (Roche, Indianapolis, IN) for 1 min, pelleted, and resuspended in NH4Cl red blood cell (RBC) lysis buffer for 1 min at RT. A single-cell suspension was made by filtering through a 40 µm mesh strainer (BD, East Rutherford, NJ) into 5 mL HF.

To detect Gpr125-β-gal expression, cells were labeled with fluorescein di-V-galactoside (FDG) according to the manufacturer’s protocol as follows (Molecular Probes, Eugene, Oregon). MECs were prepared as described above from 3 to 4 mice/genotype. For FDG staining, cells were resuspended at 10⁷/mL in HBSS supplemented with 2% FBS, and the samples were pre-warmed at 37 °C for 10 min. FDG loading was performed by adding an equal volume of pre-warmed 2 mM FDG (diluted in distilled water) to the cell suspension for exactly 1 min at 37 °C, then immediately quenched by adding 2 mL ice-cold HF. The FDG-loaded cells were then centrifuged 1000 × g and stained with surface antibodies. The following antibodies were used to label cells for flow cytometry: biotinylated- TER119 (BD 553672,1:200), biotinylated-CD31 (BD 558737,1:200), biotinylated-CD45 (BD 553077,1:200), biotinylated-CD140a (eBioscience 12-1401-80,1:200), CD24-PE (BD 553262,1:400), CD49f-PerCP-Cy5.5 (Biolegend 313617,1:200,), CD49f-PE-Cy7(BD 313621 1:200), CD24-FITC (BD553261,1:100), CD49f-PE (BD 313611 1:100), Streptavidin-AlexaFluor647 (Molecular Probes S21374,1:600), CD61-APC (Caltag,1:200), Sca1-PE-Cy7 (eBioscience 25-5981-81,1:600), CD29-Pacific Blue (Biolegend 102224,1:200). Cells were incubated with conjugated antibodies diluted in HF, for 30 min on ice in a dark container, washed with 2 mL of HF, and resuspended in 250 μL HF for analysis. Cell viability was assessed by adding 4′,6-Diamidino-2-phenylindole (DAPI, Sigma-Aldrich) to the final suspension at a concentration of 1 μg/mL. Data collection for flow cytometry was done on a Beckton-Dickinson (East Rutherford, NJ) LSRII analyser. Analyses were done using FlowJo software version 9. Gating strategy is reported in Supplementary Fig. 8. For cell sorting, cells were stained as described above, and FDG+/CD49f^hi and FDG-/CD49f^hi were sorted using FACSAria IIu and processed for mRNA extraction.

MECs were prepared as described above. Cleared fat pads from 3-week-old female FoxN1^nu mice were transplanted with 10⁵ MECs in 50/50 Matrigel/minimal medium obtained from a #4 inguinal gland from (n = 4) 7-week-old Adgra3-CreER^T2;Rosa26^tdT mice that were injected at puberty with Tam to assess the potency of Gpr125 parental cells. Mammary outgrowths of recipient glands (n = 4) were analyzed 3 weeks later by 3D imaging to assess the potency of Adgra3 cells. The remaining #4 inguinal gland of the donor Adgra3-CreER^T2; Rosa26^tdT mice (n = 4) were harvested and analyzed as controls of this experiment.

GPR125 mRNA expression in murine and human samples of breast cancer was obtained by using microarray data GSE3165 (https://www.ncbi.nlm.nih.gov/geo/). Analysis was conducted using GEO2R. Version info: R 3.2.3, Biobase 2.30.0, GEOquery 2.40.0, limma 3.26.8.

Analysis of GPR125 in human breast cancer was carried out using kmplotter https://kmplot.com/analysis/index.php?p=service&cancer=breast with criteria: Gpr125 affy ID 210473_s_at, Auto select best cutoff, excluding biased arrays and selecting for basal-type breast cancer RFS: N = 618; DMSF: N = 232 and using BreastMark: http://glados.ucd.ie/BreastMark/mRNA_custom.html DFS, median cut off was selected for ssp2003 basal-type (N = 318)⁷³ or ssp2006 basal-type (N = 366)⁷⁴ datasets.

Statistical significance was determined using GraphPad Prism software v.9.2.0. Normal distribution of data was assessed using Shapiro-Wilk normality tests. Unpaired Student’s t-test or Mann–Whitney tests were performed as reported in the figure legends and “Support data” file. Data are always expressed as mean ± SEM. p-values. In all experiments n =  number of biological replicates as indicated in the Fig. legends.

Further information on research design is available in the Nature Research Reporting Summary linked to this article.